86
Views
6
CrossRef citations to date
0
Altmetric
Addendum

Bococizumab for the treatment of hypercholesterolaemia

ORCID Icon, ORCID Icon, & ORCID Icon

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

M. Ruscica, N. Ferri, C. Macchi, A. Corsini & C. R. Sirtori. (2018) Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. Annals of Medicine 50:6, pages 461-484.
Read now

Articles from other publishers (5)

Nicola Ferri, Maria Francesca Greco, Alberto Corsini & Massimiliano Ruscica. (2020) Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies. European Heart Journal Supplements 22:Supplement_E, pages E64-E67.
Crossref
C Macchi, M Banach, A Corsini, CR Sirtori, N Ferri & M Ruscica. (2019) Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. European Journal of Preventive Cardiology 26:9, pages 930-949.
Crossref
Patchareeya Amput, Christian McSweeney, Siripong Palee, Arintaya Phrommintikul, Siriporn C. Chattipakorn & Nipon Chattipakorn. (2019) The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function. Biomedicine & Pharmacotherapy 109, pages 1171-1180.
Crossref
Barry Gumbiner, Tenshang Joh, Hong Liang, Hong Wan, Matteo Levisetti, Alicia M. Vana, David L. Shelton, Philippe Forgues, Stephan Billotte, Jaume Pons, Charles M. Baum & Pamela D. Garzone. (2018) The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastati. Cardiovascular Therapeutics 36:1, pages e12309.
Crossref
Sergio Fazio, David G. Robertson, Tenshang Joh, Hong Wan, Tom Riel, Philippe Forgues, Charles M. Baum, Pamela D. Garzone & Barry Gumbiner. (2018) Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin. Cardiovascular Therapeutics 36:1, pages e12308.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.